Needham Reiterates Buy Rating for NMRA
Needham maintains its Buy rating on NMRA, targeting $5, a 447.05% upside from the current price.
Key Points
- Needham reiterated its Buy rating for NMRA on June 16, 2026, with a target price of $5.
- Needham's $5 price target implies 447.05% upside from Neumora Therapeutics, Inc.'s ($NMRA) current $0.91 share price.
- NMRA shares were trading at $0.91, reflecting ongoing interest from both analysts and insiders.
- Insider buying activity was noted with multiple insiders acquiring 80,000 shares each on May 27, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Needham reiterated its Buy rating for NMRA on June 16, 2026, setting a target price of $5. The analyst, Ami Fadia, continued to show confidence in the company's prospects, maintaining the previous rating.
Other Institutional Activity in NMRA
SIREN, L.L.C. increased its holdings in NMRA by 2,209,039 shares, bringing its total to 8,497,822 shares valued at about $16.57 million. SOFTBANK GROUP CORP. reduced its position by 339,419 shares, holding 6,090,301 shares worth approximately $11.88 million. Perceptive Advisors LLC initiated a new position with 5,104,097 shares valued at $9.95 million. MIC Capital Management UK LLP kept its stake unchanged, holding 4,460,700 shares valued at $8.70 million. Vanguard Capital Management LLC also started a new position with 3,891,893 shares worth $7.59 million.
Neumora Therapeutics, Inc. Stock Down 34.2%
Shares of NMRA were trading at $0.91. The stock has seen varied interest from both institutional investors and analysts, reflecting its potential despite its current low trading price.
Insider Buying and Selling at Neumora Therapeutics, Inc.
On May 27, 2026, several insiders, including Matthew Fust, Maykin Ho, Kristina Burow, Alaa Halawa, and David Piacquad, each acquired 80,000 shares at no reported price, indicating potential confidence in the company's future. Earlier in the year, on February 17, 2026, Michael Lee Milligan, the Chief Financial Officer and Principal Accounting Officer, sold 1,436 shares at an average price of $3.56.
Analysts Set New Price Targets
On June 16, 2026, Needham maintained its Buy rating for NMRA with a target price of $5. HC Wainwright & Co. also maintained a Buy rating, setting a higher target of $7. Guggenheim reiterated a Buy rating on March 31, 2026, with a target of $14, showing varied optimism among analysts.
Bottom Line
Needham's reiterated Buy rating and $5 target for NMRA suggest ongoing confidence from analysts. The stock's low trading price of $0.91, combined with insider buying, indicates that investors are keeping an eye on its potential. As always, it's important to remember that 13F filings and analyst ratings are backward-looking and may not reflect the most current conditions.
Get Neumora Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NMRA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.